Clyde Wright
Concepts (363)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchopulmonary Dysplasia | 21 | 2024 | 403 | 7.170 |
Why?
| | Acetaminophen | 15 | 2025 | 264 | 7.030 |
Why?
| | NF-kappa B | 23 | 2024 | 690 | 6.990 |
Why?
| | Respiratory Distress Syndrome, Newborn | 12 | 2023 | 106 | 6.750 |
Why?
| | Endotoxemia | 10 | 2024 | 87 | 6.060 |
Why?
| | Pulmonary Surfactants | 10 | 2023 | 105 | 5.520 |
Why?
| | I-kappa B Proteins | 13 | 2022 | 76 | 4.560 |
Why?
| | Liver | 16 | 2024 | 1817 | 4.180 |
Why?
| | Continuous Positive Airway Pressure | 12 | 2022 | 93 | 3.620 |
Why?
| | Ductus Arteriosus, Patent | 8 | 2024 | 53 | 3.610 |
Why?
| | Lung Injury | 7 | 2022 | 227 | 3.030 |
Why?
| | Lung | 20 | 2025 | 4129 | 2.840 |
Why?
| | Infant, Premature, Diseases | 5 | 2021 | 107 | 2.680 |
Why?
| | Immunity, Innate | 10 | 2024 | 852 | 2.670 |
Why?
| | Infant, Newborn | 46 | 2024 | 6262 | 2.590 |
Why?
| | Noninvasive Ventilation | 5 | 2022 | 59 | 2.460 |
Why?
| | Infant, Premature | 15 | 2024 | 598 | 2.400 |
Why?
| | Signal Transduction | 19 | 2025 | 5153 | 2.200 |
Why?
| | Hyperoxia | 7 | 2017 | 91 | 1.870 |
Why?
| | Transcription Factor RelA | 4 | 2024 | 85 | 1.800 |
Why?
| | Animals, Newborn | 13 | 2024 | 867 | 1.750 |
Why?
| | Surface-Active Agents | 8 | 2023 | 92 | 1.690 |
Why?
| | Infant, Extremely Premature | 8 | 2024 | 66 | 1.690 |
Why?
| | Mice, Inbred ICR | 12 | 2021 | 118 | 1.670 |
Why?
| | Ibuprofen | 5 | 2024 | 83 | 1.460 |
Why?
| | Lipopolysaccharides | 9 | 2024 | 888 | 1.410 |
Why?
| | Neonatology | 3 | 2025 | 29 | 1.400 |
Why?
| | Biological Products | 3 | 2021 | 239 | 1.390 |
Why?
| | Toll-Like Receptor 4 | 3 | 2023 | 276 | 1.360 |
Why?
| | Chemical and Drug Induced Liver Injury | 2 | 2022 | 138 | 1.350 |
Why?
| | Oxygen | 6 | 2022 | 992 | 1.300 |
Why?
| | Macrophages | 7 | 2020 | 1563 | 1.230 |
Why?
| | Apoptosis | 6 | 2024 | 2575 | 1.230 |
Why?
| | Inflammation | 5 | 2024 | 2895 | 1.140 |
Why?
| | Evidence-Based Medicine | 4 | 2021 | 715 | 1.130 |
Why?
| | Airway Extubation | 2 | 2020 | 60 | 1.120 |
Why?
| | Mice | 30 | 2025 | 18092 | 1.120 |
Why?
| | NF-kappa B p50 Subunit | 4 | 2023 | 23 | 1.110 |
Why?
| | Animals | 40 | 2025 | 37642 | 1.070 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2024 | 1241 | 1.030 |
Why?
| | Infant, Newborn, Diseases | 2 | 2019 | 113 | 0.960 |
Why?
| | Cytochrome P-450 CYP2E1 | 5 | 2025 | 30 | 0.950 |
Why?
| | Fetal Growth Retardation | 5 | 2024 | 582 | 0.910 |
Why?
| | Pregnancy | 15 | 2024 | 7039 | 0.880 |
Why?
| | Humans | 71 | 2025 | 141267 | 0.870 |
Why?
| | Mice, Inbred C57BL | 13 | 2025 | 5901 | 0.850 |
Why?
| | Transcription Factor AP-1 | 1 | 2024 | 88 | 0.820 |
Why?
| | Disease Models, Animal | 13 | 2024 | 4413 | 0.800 |
Why?
| | Physician's Role | 2 | 2021 | 217 | 0.790 |
Why?
| | Gene Expression Regulation | 8 | 2021 | 2608 | 0.780 |
Why?
| | Interleukin-1alpha | 2 | 2020 | 57 | 0.760 |
Why?
| | Interleukin-1beta | 3 | 2020 | 386 | 0.720 |
Why?
| | Premature Birth | 3 | 2022 | 363 | 0.710 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2021 | 270 | 0.710 |
Why?
| | Streptozocin | 1 | 2021 | 22 | 0.700 |
Why?
| | Selenoproteins | 1 | 2020 | 7 | 0.680 |
Why?
| | Cyclooxygenase Inhibitors | 2 | 2024 | 83 | 0.640 |
Why?
| | Toll-Like Receptor 9 | 1 | 2020 | 33 | 0.640 |
Why?
| | Ovarian Follicle | 1 | 2020 | 72 | 0.630 |
Why?
| | Monocytes | 1 | 2023 | 578 | 0.630 |
Why?
| | Chorioamnionitis | 1 | 2020 | 45 | 0.630 |
Why?
| | Oxidative Stress | 3 | 2017 | 1327 | 0.630 |
Why?
| | Acidosis | 1 | 2020 | 102 | 0.600 |
Why?
| | Uterus | 1 | 2020 | 221 | 0.590 |
Why?
| | Emphysema | 1 | 2019 | 116 | 0.580 |
Why?
| | Oximetry | 2 | 2017 | 127 | 0.580 |
Why?
| | Inflammation Mediators | 3 | 2019 | 517 | 0.560 |
Why?
| | I-kappa B Kinase | 2 | 2021 | 54 | 0.560 |
Why?
| | Interferon-beta | 1 | 2018 | 94 | 0.560 |
Why?
| | Calcium Signaling | 1 | 2020 | 249 | 0.550 |
Why?
| | Gestational Age | 4 | 2024 | 952 | 0.550 |
Why?
| | Fetus | 4 | 2020 | 799 | 0.550 |
Why?
| | Treatment Failure | 2 | 2019 | 354 | 0.550 |
Why?
| | Sugars | 1 | 2018 | 42 | 0.540 |
Why?
| | Beverages | 1 | 2018 | 65 | 0.540 |
Why?
| | Respiration, Artificial | 5 | 2022 | 686 | 0.530 |
Why?
| | Mediastinal Emphysema | 1 | 2017 | 8 | 0.530 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 251 | 0.520 |
Why?
| | Gene Expression | 3 | 2024 | 1492 | 0.510 |
Why?
| | Respiration | 2 | 2018 | 211 | 0.510 |
Why?
| | Peer Review, Research | 1 | 2017 | 31 | 0.510 |
Why?
| | Standard of Care | 1 | 2017 | 77 | 0.500 |
Why?
| | Insulin-Secreting Cells | 1 | 2021 | 380 | 0.500 |
Why?
| | Infant, Small for Gestational Age | 1 | 2017 | 103 | 0.500 |
Why?
| | Respiratory System | 1 | 2017 | 157 | 0.490 |
Why?
| | Immune Tolerance | 1 | 2018 | 374 | 0.490 |
Why?
| | Asphyxia Neonatorum | 1 | 2016 | 18 | 0.480 |
Why?
| | Male | 27 | 2025 | 70063 | 0.470 |
Why?
| | Intensive Care Units, Neonatal | 4 | 2022 | 268 | 0.470 |
Why?
| | Cyclooxygenase 2 | 1 | 2016 | 175 | 0.460 |
Why?
| | Mice, Knockout | 4 | 2025 | 3065 | 0.460 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 323 | 0.460 |
Why?
| | Nitric Oxide | 3 | 2019 | 898 | 0.450 |
Why?
| | Milk, Human | 1 | 2017 | 169 | 0.450 |
Why?
| | Hypothermia, Induced | 1 | 2016 | 92 | 0.440 |
Why?
| | Child Advocacy | 2 | 2005 | 32 | 0.440 |
Why?
| | Caloric Restriction | 3 | 2024 | 126 | 0.430 |
Why?
| | Fetal Diseases | 1 | 2016 | 180 | 0.430 |
Why?
| | NF-KappaB Inhibitor alpha | 4 | 2020 | 50 | 0.420 |
Why?
| | Intestinal Atresia | 1 | 2014 | 15 | 0.420 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 634 | 0.420 |
Why?
| | Endothelin-1 | 1 | 2015 | 177 | 0.420 |
Why?
| | Calcium | 1 | 2020 | 1191 | 0.420 |
Why?
| | Interleukin-6 | 3 | 2025 | 777 | 0.410 |
Why?
| | Infant | 10 | 2024 | 9801 | 0.410 |
Why?
| | Sex Characteristics | 1 | 2019 | 786 | 0.410 |
Why?
| | Ethics Committees, Research | 1 | 2013 | 41 | 0.400 |
Why?
| | MicroRNAs | 3 | 2024 | 694 | 0.400 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2013 | 70 | 0.400 |
Why?
| | Resuscitation | 1 | 2016 | 283 | 0.390 |
Why?
| | Cytomegalovirus Infections | 1 | 2015 | 197 | 0.390 |
Why?
| | Visual Perception | 1 | 2015 | 177 | 0.390 |
Why?
| | Intestine, Small | 1 | 2014 | 157 | 0.380 |
Why?
| | Hepatocytes | 3 | 2024 | 212 | 0.380 |
Why?
| | Female | 27 | 2025 | 75729 | 0.380 |
Why?
| | Fibroblasts | 3 | 2015 | 1019 | 0.370 |
Why?
| | Pediatrics | 3 | 2005 | 1099 | 0.370 |
Why?
| | Catheterization, Peripheral | 1 | 2013 | 108 | 0.370 |
Why?
| | Abnormalities, Multiple | 1 | 2014 | 197 | 0.370 |
Why?
| | Phospholipids | 1 | 2013 | 221 | 0.360 |
Why?
| | Respiration Disorders | 1 | 2012 | 79 | 0.360 |
Why?
| | Urinary Bladder | 1 | 2014 | 195 | 0.350 |
Why?
| | Fetal Blood | 2 | 2024 | 336 | 0.350 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2018 | 1605 | 0.350 |
Why?
| | Colon | 1 | 2014 | 296 | 0.350 |
Why?
| | Biomarkers | 3 | 2024 | 4179 | 0.340 |
Why?
| | Clinical Competence | 1 | 2019 | 1197 | 0.340 |
Why?
| | Microcirculation | 1 | 2010 | 150 | 0.320 |
Why?
| | Neuropsychological Tests | 1 | 2015 | 1089 | 0.320 |
Why?
| | Patient Safety | 1 | 2013 | 336 | 0.310 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2021 | 174 | 0.310 |
Why?
| | Glycolysis | 2 | 2021 | 326 | 0.300 |
Why?
| | RAW 264.7 Cells | 2 | 2020 | 49 | 0.300 |
Why?
| | Cells, Cultured | 5 | 2019 | 4205 | 0.300 |
Why?
| | Analgesics, Non-Narcotic | 3 | 2024 | 127 | 0.290 |
Why?
| | Cell Line | 4 | 2017 | 2880 | 0.290 |
Why?
| | Body Mass Index | 1 | 2017 | 2377 | 0.290 |
Why?
| | Indomethacin | 3 | 2024 | 87 | 0.290 |
Why?
| | Curriculum | 2 | 2005 | 1030 | 0.280 |
Why?
| | Hydrocortisone | 2 | 2020 | 309 | 0.270 |
Why?
| | Cytokines | 3 | 2023 | 2093 | 0.260 |
Why?
| | Cognition | 1 | 2015 | 1224 | 0.250 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 950 | 0.250 |
Why?
| | Gene Silencing | 2 | 2021 | 198 | 0.240 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2020 | 142 | 0.240 |
Why?
| | Neonatologists | 1 | 2025 | 8 | 0.230 |
Why?
| | History, 20th Century | 2 | 2017 | 325 | 0.230 |
Why?
| | Biological Evolution | 1 | 2009 | 488 | 0.230 |
Why?
| | Endothelial Cells | 1 | 2010 | 814 | 0.220 |
Why?
| | Cell Survival | 3 | 2021 | 1131 | 0.220 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2020 | 875 | 0.220 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2025 | 94 | 0.220 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2025 | 132 | 0.220 |
Why?
| | Internship and Residency | 2 | 2005 | 1225 | 0.210 |
Why?
| | Patient Advocacy | 1 | 2005 | 74 | 0.210 |
Why?
| | Cell Nucleus | 2 | 2019 | 610 | 0.210 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2024 | 56 | 0.210 |
Why?
| | RNA, Messenger | 4 | 2024 | 2826 | 0.210 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2024 | 73 | 0.210 |
Why?
| | STAT3 Transcription Factor | 1 | 2025 | 211 | 0.200 |
Why?
| | Research Personnel | 1 | 2025 | 177 | 0.200 |
Why?
| | Toll-Like Receptor 1 | 1 | 2023 | 12 | 0.200 |
Why?
| | Zymosan | 1 | 2023 | 66 | 0.200 |
Why?
| | Intensive Care, Neonatal | 1 | 2023 | 40 | 0.200 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2023 | 91 | 0.190 |
Why?
| | Infant, Low Birth Weight | 1 | 2023 | 145 | 0.190 |
Why?
| | Toll-Like Receptors | 1 | 2023 | 189 | 0.180 |
Why?
| | Ligation | 1 | 2022 | 93 | 0.180 |
Why?
| | Age Factors | 2 | 2020 | 3292 | 0.180 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2024 | 208 | 0.180 |
Why?
| | Morbidity | 2 | 2021 | 320 | 0.180 |
Why?
| | Hepatic Veins | 1 | 2021 | 31 | 0.180 |
Why?
| | Dilatation | 1 | 2022 | 69 | 0.180 |
Why?
| | Dyspnea | 1 | 2023 | 258 | 0.180 |
Why?
| | Insulinoma | 1 | 2021 | 27 | 0.170 |
Why?
| | Feces | 1 | 2024 | 493 | 0.170 |
Why?
| | Chemokine CXCL10 | 1 | 2021 | 38 | 0.170 |
Why?
| | Transcription Factors | 1 | 2009 | 1707 | 0.170 |
Why?
| | Vascular Malformations | 1 | 2021 | 50 | 0.170 |
Why?
| | Glutathione Peroxidase | 1 | 2020 | 43 | 0.170 |
Why?
| | TNF Receptor-Associated Factor 1 | 1 | 2020 | 8 | 0.170 |
Why?
| | C-Reactive Protein | 1 | 2023 | 417 | 0.170 |
Why?
| | Chemokine CCL3 | 1 | 2020 | 17 | 0.170 |
Why?
| | Selenium | 1 | 2020 | 49 | 0.160 |
Why?
| | Ventilator Weaning | 1 | 2020 | 39 | 0.160 |
Why?
| | Portal Vein | 1 | 2021 | 109 | 0.160 |
Why?
| | Calcineurin Inhibitors | 1 | 2020 | 70 | 0.160 |
Why?
| | Oxidative Phosphorylation | 1 | 2021 | 205 | 0.160 |
Why?
| | Intermittent Positive-Pressure Ventilation | 1 | 2019 | 12 | 0.160 |
Why?
| | Homeostasis | 1 | 2024 | 636 | 0.160 |
Why?
| | Chelating Agents | 1 | 2020 | 73 | 0.160 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2020 | 143 | 0.160 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2021 | 196 | 0.150 |
Why?
| | Norepinephrine | 1 | 2020 | 189 | 0.150 |
Why?
| | Primary Cell Culture | 1 | 2020 | 171 | 0.150 |
Why?
| | Proteolysis | 1 | 2020 | 173 | 0.150 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 348 | 0.150 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2019 | 111 | 0.150 |
Why?
| | Chemokine CXCL1 | 1 | 2019 | 79 | 0.150 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2018 | 17 | 0.150 |
Why?
| | Biomedical Research | 1 | 2025 | 681 | 0.150 |
Why?
| | Mitochondria | 1 | 2025 | 975 | 0.150 |
Why?
| | Spleen | 1 | 2020 | 522 | 0.140 |
Why?
| | Cytosol | 1 | 2019 | 229 | 0.140 |
Why?
| | STAT1 Transcription Factor | 1 | 2018 | 71 | 0.140 |
Why?
| | Morphogenesis | 1 | 2019 | 171 | 0.140 |
Why?
| | Consensus | 1 | 2021 | 546 | 0.140 |
Why?
| | Weight Gain | 2 | 2023 | 537 | 0.140 |
Why?
| | Delivery Rooms | 1 | 2018 | 10 | 0.140 |
Why?
| | Receptors, CCR2 | 1 | 2018 | 39 | 0.140 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2018 | 18 | 0.140 |
Why?
| | Rotation | 1 | 2018 | 121 | 0.140 |
Why?
| | Protective Agents | 1 | 2018 | 41 | 0.140 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2024 | 656 | 0.130 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 83 | 0.130 |
Why?
| | Sheep | 1 | 2020 | 872 | 0.130 |
Why?
| | Overnutrition | 1 | 2017 | 30 | 0.130 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2018 | 147 | 0.130 |
Why?
| | Hypertension, Pulmonary | 2 | 2019 | 1941 | 0.130 |
Why?
| | Ductus Arteriosus | 1 | 2017 | 73 | 0.130 |
Why?
| | Pennsylvania | 1 | 2017 | 134 | 0.130 |
Why?
| | Parturition | 1 | 2017 | 67 | 0.130 |
Why?
| | Conservative Treatment | 1 | 2017 | 35 | 0.130 |
Why?
| | Calibration | 1 | 2017 | 152 | 0.130 |
Why?
| | Disease Susceptibility | 1 | 2018 | 352 | 0.130 |
Why?
| | Protective Factors | 1 | 2016 | 96 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 723 | 0.120 |
Why?
| | Physicians | 1 | 2025 | 929 | 0.120 |
Why?
| | Positive-Pressure Respiration | 1 | 2017 | 107 | 0.120 |
Why?
| | Primary Prevention | 1 | 2018 | 202 | 0.120 |
Why?
| | History, 21st Century | 1 | 2017 | 218 | 0.120 |
Why?
| | Health Status Disparities | 1 | 2019 | 300 | 0.120 |
Why?
| | RNA, Small Interfering | 2 | 2016 | 628 | 0.120 |
Why?
| | Time-to-Treatment | 1 | 2018 | 224 | 0.120 |
Why?
| | Vascular Remodeling | 1 | 2018 | 196 | 0.120 |
Why?
| | Up-Regulation | 1 | 2019 | 856 | 0.120 |
Why?
| | Cholestasis | 1 | 2018 | 209 | 0.120 |
Why?
| | Macaca mulatta | 1 | 2016 | 189 | 0.110 |
Why?
| | Precision Medicine | 1 | 2019 | 435 | 0.110 |
Why?
| | Cell Proliferation | 3 | 2011 | 2504 | 0.110 |
Why?
| | Adult | 6 | 2025 | 39203 | 0.110 |
Why?
| | Administration, Oral | 1 | 2017 | 824 | 0.110 |
Why?
| | Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2014 | 3 | 0.110 |
Why?
| | Periodicals as Topic | 1 | 2017 | 198 | 0.110 |
Why?
| | Prune Belly Syndrome | 1 | 2014 | 8 | 0.110 |
Why?
| | Body Composition | 1 | 2018 | 703 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 85 | 0.100 |
Why?
| | Interleukins | 1 | 2015 | 250 | 0.100 |
Why?
| | Cell Line, Tumor | 1 | 2021 | 3504 | 0.100 |
Why?
| | Syndrome | 1 | 2014 | 378 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2021 | 1543 | 0.100 |
Why?
| | Breast Feeding | 1 | 2017 | 442 | 0.100 |
Why?
| | Kidney | 1 | 2020 | 1482 | 0.100 |
Why?
| | Pilot Projects | 1 | 2018 | 1815 | 0.090 |
Why?
| | Child | 4 | 2018 | 22342 | 0.090 |
Why?
| | Brain Injuries | 1 | 2017 | 502 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2072 | 0.090 |
Why?
| | Hydrogen Peroxide | 1 | 2014 | 339 | 0.090 |
Why?
| | Transcriptome | 1 | 2019 | 1010 | 0.090 |
Why?
| | Rats | 2 | 2013 | 5595 | 0.090 |
Why?
| | Culture Media, Serum-Free | 1 | 2012 | 46 | 0.090 |
Why?
| | Gene Knock-In Techniques | 1 | 2012 | 59 | 0.090 |
Why?
| | Risk Assessment | 2 | 2019 | 3515 | 0.090 |
Why?
| | Cell Line, Transformed | 1 | 2012 | 145 | 0.090 |
Why?
| | Software | 1 | 2017 | 676 | 0.090 |
Why?
| | Retinopathy of Prematurity | 1 | 2013 | 161 | 0.090 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2011 | 15 | 0.090 |
Why?
| | Mice, Mutant Strains | 1 | 2012 | 306 | 0.090 |
Why?
| | Radiography | 1 | 2014 | 847 | 0.090 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 350 | 0.080 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2923 | 0.080 |
Why?
| | Cohort Studies | 2 | 2019 | 5802 | 0.080 |
Why?
| | Mice, Transgenic | 1 | 2015 | 2178 | 0.080 |
Why?
| | Protoporphyrins | 1 | 2009 | 16 | 0.080 |
Why?
| | Caspase 3 | 1 | 2010 | 248 | 0.080 |
Why?
| | Cyclin D1 | 1 | 2009 | 68 | 0.080 |
Why?
| | Heme Oxygenase-1 | 1 | 2009 | 63 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1493 | 0.080 |
Why?
| | Circadian Rhythm | 1 | 2014 | 509 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2524 | 0.080 |
Why?
| | Antioxidants | 1 | 2013 | 597 | 0.070 |
Why?
| | Luciferases | 1 | 2008 | 148 | 0.070 |
Why?
| | Pulmonary Alveoli | 1 | 2011 | 413 | 0.070 |
Why?
| | Genes, Reporter | 1 | 2008 | 272 | 0.070 |
Why?
| | Tyrosine | 1 | 2008 | 229 | 0.070 |
Why?
| | Child, Preschool | 2 | 2018 | 11473 | 0.070 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2008 | 377 | 0.070 |
Why?
| | Amino Acid Substitution | 1 | 2008 | 309 | 0.070 |
Why?
| | Blood Glucose | 1 | 2018 | 2275 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2012 | 1769 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2522 | 0.070 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 184 | 0.070 |
Why?
| | Placenta | 2 | 2024 | 764 | 0.060 |
Why?
| | Aging | 1 | 2017 | 1921 | 0.060 |
Why?
| | United States | 3 | 2025 | 15245 | 0.060 |
Why?
| | Transfection | 1 | 2008 | 936 | 0.060 |
Why?
| | Risk Factors | 2 | 2019 | 10482 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 843 | 0.060 |
Why?
| | Recombinant Proteins | 1 | 2008 | 1369 | 0.060 |
Why?
| | Base Sequence | 1 | 2008 | 2172 | 0.060 |
Why?
| | Research Support as Topic | 1 | 2025 | 81 | 0.060 |
Why?
| | Wisconsin | 1 | 2005 | 99 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2011 | 2001 | 0.060 |
Why?
| | Pregnancy Trimester, Third | 1 | 2024 | 113 | 0.050 |
Why?
| | Phosphorylation | 1 | 2008 | 1760 | 0.050 |
Why?
| | Amniotic Fluid | 1 | 2024 | 79 | 0.050 |
Why?
| | Career Choice | 1 | 2025 | 233 | 0.050 |
Why?
| | Job Satisfaction | 1 | 2025 | 225 | 0.050 |
Why?
| | Prenatal Diagnosis | 1 | 2024 | 190 | 0.050 |
Why?
| | Program Development | 1 | 2005 | 364 | 0.050 |
Why?
| | Diet, High-Fat | 1 | 2023 | 250 | 0.050 |
Why?
| | Educational Measurement | 1 | 2005 | 315 | 0.050 |
Why?
| | DNA | 1 | 2008 | 1441 | 0.050 |
Why?
| | Child Health Services | 1 | 2004 | 196 | 0.050 |
Why?
| | Data Collection | 1 | 2005 | 654 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2024 | 1042 | 0.040 |
Why?
| | Models, Biological | 1 | 2008 | 1826 | 0.040 |
Why?
| | Program Evaluation | 1 | 2005 | 919 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2023 | 550 | 0.040 |
Why?
| | Fetal Development | 1 | 2023 | 296 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2005 | 524 | 0.040 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2019 | 20 | 0.040 |
Why?
| | Caspases, Initiator | 1 | 2018 | 17 | 0.040 |
Why?
| | Liver X Receptors | 1 | 2018 | 30 | 0.040 |
Why?
| | Glucose | 1 | 2023 | 1033 | 0.040 |
Why?
| | Ketanserin | 1 | 2018 | 12 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2019 | 594 | 0.040 |
Why?
| | Serotonin Antagonists | 1 | 2018 | 31 | 0.030 |
Why?
| | Caspase 1 | 1 | 2018 | 147 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2018 | 215 | 0.030 |
Why?
| | Caspases | 1 | 2018 | 245 | 0.030 |
Why?
| | Parenteral Nutrition | 1 | 2018 | 105 | 0.030 |
Why?
| | Lipoproteins | 1 | 2018 | 163 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2018 | 133 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2024 | 3580 | 0.030 |
Why?
| | Bleomycin | 1 | 2018 | 248 | 0.030 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 208 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 341 | 0.030 |
Why?
| | Social Determinants of Health | 1 | 2019 | 273 | 0.030 |
Why?
| | Comet Assay | 1 | 2014 | 16 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2025 | 5937 | 0.020 |
Why?
| | Prospective Studies | 1 | 2024 | 7787 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2011 | 53 | 0.020 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 50 | 0.020 |
Why?
| | DNA Damage | 1 | 2014 | 430 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 123 | 0.020 |
Why?
| | Binding Sites | 1 | 2014 | 1315 | 0.020 |
Why?
| | Injections | 1 | 2011 | 191 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2011 | 327 | 0.020 |
Why?
| | Sp1 Transcription Factor | 1 | 2009 | 25 | 0.020 |
Why?
| | Early Growth Response Protein 1 | 1 | 2009 | 29 | 0.020 |
Why?
| | Hep G2 Cells | 1 | 2009 | 71 | 0.020 |
Why?
| | K562 Cells | 1 | 2009 | 95 | 0.020 |
Why?
| | Response Elements | 1 | 2009 | 89 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2009 | 175 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 801 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2009 | 295 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 758 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1271 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2024 | 16373 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2011 | 1114 | 0.010 |
Why?
| | Middle Aged | 1 | 2025 | 34597 | 0.010 |
Why?
| | Time Factors | 1 | 2011 | 6971 | 0.010 |
Why?
|
|
Wright's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|